NCT06212336

ISTH/ANRS 0409s INTEGRATE Lassa Fever Study

Efficacy, Tolerability and Safety of New or Repurposed Drugs Against Lassa Fever in West African Countries

• Status: Recruiting
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 1,755 (estimated)
• Sponsor: Irrua Specialist Teaching Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Lassa fever (LF) is a viral haemorrhagic fever responsible of 5000 deaths per year in West Africa, with in-hospital mortality at 12%. Transmission to humans occurs mainly via direct or indirect exposure to excreta from the rodent reservoir, mainly made up of Mastomys natalensis . Less frequently, LASV may also be transmitted from human to human and cause nosocomial outbreaks. Ribavirin is the only treatment available with worrying toxicity, questionable efficacy and low access because of its high cost. Consequently, there is an urgent need for new drugs to treat LF patients. The Research and Development (R\&D) Blueprint of the World Health Organization (WHO) has included LF in the list of priority diseases for urgent research and development. The INTEGRATE consortium is an unprecedented international collaboration on Lassa fever of 15 partners from 10 countries across West Africa, Europe and North America and across several disciplines (epidemiological researchers, social scientists, medical health facility professionals, humanitarian actors, etc.).

Detailed description

The INTEGRATE study is a platform, multinational, multicentre, sequential, seamless phase II-III, controlled, randomised, superiority trial in open-label parallel arms. Three arms will be assessed and compared to the SCD. Its primary objective is to compare the efficacy of each Investigational Medical Product (IMP) to Standard of Care Drug (SCD) to prevent death or organ failure in hospitalized patients with confirmed LF. Secondary objectives will be i) to compare the safety and tolerability of each IMP and SCD, ii) to compare the efficacy of each IMP and SCD on clinical, virological and biological parameters, iii) to describe the pharmacokinetics of each IMP and iv) to develop a pharmacokinetics / pharmacodynamics model for each IMP informing about optimal dosing regimens and dose-response relationship. 1. Objectives 1.1 Primary objective The primary objective of the trial is to compare the efficacy of each IMP and SCD to prevent death or organ failure in hospitalized participants with confirmed LF. 1.2. Secondary objectives * To compare the safety and tolerability of each IMP and SCD * To compare the efficacy of each IMP and SCD on clinical, virological and biological parameters * To describe the pharmacokinetics of each IMP * To develop a pharmacokinetics / pharmacodynamics model for each IMP informing about optimal dosing regimens and dose-response relationship 2. Design * Phase II: comparative controlled design * Phase III: Whitehead's sequential double triangular design 3. Sample size: In the current version of the protocol (if all sub-protocols start at once): * 3 IMPs go into phase III: N= 732 * 2 IMPs go into phase III: N= 585 * 1 IMP go into phase III: N= 438 4. Duration * Hospitalization: 10 days * Follow-up: 28 days

Conditions

• Lassa Fever

Interventions

Type	Name	Description
DRUG	Favipiravir	Interventional Medicinal Product (IMP)
DRUG	Ribavirin	Control arm
DRUG	Dexamethasone	Interventional Medicinal Product (IMP)
DRUG	ARN-75039 high dose	Investigational Medicinal Product
DRUG	ARN-75039 low dose	Investigational Medicinal Product

Timeline

• Start date: 2025-05-02
• Primary completion: 2027-06-01
• Completion: 2027-06-01
• First posted: 2024-01-18
• Last updated: 2026-02-04

Locations

4 sites across 2 countries: Liberia, Nigeria

Regulatory

• FDA-regulated drug study